Skyhawk’s mission is to revolutionize disease treatment by developing small molecule therapeutics that correct RNA expression. Its proprietary technology enables the rational design of small molecules that target the RNA splicing process. It targets diseases driven by a type of RNA mis-splicing called "exon skipping," where key regions on the RNA are left out during the RNA splicing process. These technological advancements allow Skyhawk to develop drug candidates for cancer, neurological diseases, and other rare diseases previously thought to be undruggable.

Investment: $108,000,000

Health Care, Biotechnology, Biotherapeutics, Biopharmaceuticals, Medical Devices, R&D, B2B